Global ETD Search

461	Efeitos do ácido graxo ômega-3 na prevenção da atrofia muscular induzida pela dexametasona / Effects of omega-3 fatty acid in preventing dexamethasone-induced muscle atrophy Fappi, Alan 03 December 2013 (has links) Várias condições podem estar associadas com a atrofia muscular, tais como inatividade, envelhecimento, septicemia, diabetes, câncer e uso de glicocorticoides. Todas estas condições levam a atrofia muscular através de mecanismos que incluem aumento da degradação proteica e/ou redução na síntese proteica, envolvendo pelo menos cinco sistemas: lisossomal, da calpaína, das caspases, metaloproteinases e o sistema ubiquitina-proteasoma (SUP). Glicocorticoides, tais como a dexametasona, acarretam atrofia muscular atuando em quase todos esses sistemas, com significante ativação do SUP e lisossomal, afetando uma importante via de trofismo muscular, a via do IGF-1/PI-3K/Akt/mTOR. Ácidos graxos poli-insaturados, como o Ômega-3 (ômega-3), têm sido utilizados de forma benéfica na atenuação da atrofia muscular que ocorre na septicemia e na caquexia associada ao câncer, no entanto, sua atuação sobre a atrofia muscular induzida por glicocorticoides ainda não foi avaliada. Objetivo: Avaliar se a suplementação do ácido graxo ômega-3 influenciaria o desenvolvimento da atrofia muscular induzida pela dexametasona em ratos. Metodologia: Vinte e quatro ratos Wistar suplementados e não suplementados com ômega-3 (40 dias) foram submetidos à administração de dexametasona subcutânea (5mg/Kg/dia) nos últimos 10 dias, formando assim quatro grupos: Controle (CT), dexametasona (DX), ômega3 e dexametasona+ômega3 (DX+ômega3). Através de estudo de comportamento motor, histológico, PCR em tempo real e Western Blotting foram avaliados respectivamente, o número de grandes e pequenos movimentos em campo aberto; a área de secção transversa das fibras musculares (fibras I, IIA e IIB); a expressão dos genes MyoD, Miogenina, MuRF-1, Atrogina-1 e Miostatina; e a expressão de proteínas relacionadas com a via do IGF-1/PI-3K/Akt/mTOR: Akt, GSK3beta, FOXO3a e mTOR, totais e fosforiladas. Resultados: A dexametasona produziu diminuição na quantidade de pequenos movimentos, atrofia muscular em fibras do tipo IIB e diminuição na expressão de P-Akt, P-GSK3ômega e P-FOXO3a/FOXO3a total. A suplementação com Ômega-3 não se mostrou eficaz na atenuação de tais alterações. Por outro lado, o Ômega-3 associado à dexametasona (grupo DX+3) induziu a maior expressão de atrogenes (MuRF-1 e atrogina-1) causando, adicionalmente, maior atrofia muscular em fibras do tipo I e IIA, além de menor expressão gênica de Miogenina. O Ômega-3 de forma isolada conduziu de forma significativa a maior expressão de Miostatina e MyoD, e de forma não significante elevou a expressão proteica de mTOR total e induziu menor ganho de peso corporal dos animais ao fim do estudo. Conclusão: A suplementação de Ômega-3 não foi capaz de atenuar as alterações comportamentais, atrofia muscular e perda de peso corporal causadas pela administração de dexametasona, levando por outro lado a maior atrofia das fibras musculares e aumento na expressão de atrogenes. Desta forma, este estudo sugere que suplementos alimentares usualmente considerados benéficos para saúde, tal como o ácido graxo Ômega-3, podem agir em interação com alguns medicamentos, como os glicocorticoides, potencializando seus efeitos colaterais / Many conditions can be related to muscle atrophy, such as inactivity, aging, sepsis, diabetes, cancer, as well as, glucocorticoid treatment. All these conditions lead to muscle atrophy through mechanisms that include increase of protein degradation and/or decrease of protein synthesis involving at least five systems: lysossomal, calpain, caspases, metaloproteinases and ubiquitin proteasome system (UPS). Glucocorticoids, such as dexamethasone cause muscle atrophy acting in almost all of these systems, with a significant UPS activation and affecting an important pathway related to muscular trophism, IGF-1/PI-3k/Akt/mTOR pathway. Poly-unsaturated fatty acids, such as Omega-3 (omega-3), have been used beneficially to attenuation of muscle atrophy that occur in sepsis and cachexia related to cancer, however, its action in the glucocorticoid-induced muscle atrophy, has never been evaluated. Objective: Assess whether the omega-3 supplementation would influence the development of dexamethasone-induced muscle atrophy in rats. Methods: Twenty four Wistar rats supplemented and non-supplemented with omega-3 (40 days) were submitted to dexamethasone administration (5mg/kg/day) during the last 10 days, thus establishing 4 groups: control (CT), dexamethasone (DX), omega-3 and dexamethasone+omega-3 (DX+ omega-3). The amount of large and small movements in open field; muscle fiber cross sectional areas (I, IIA and IIB); MyoD, Myogenin, MuRF-1, Atrogin-1 and Myostatin gene expression; and protein expression of Akt, GSK3omega, FOXO3a and mTOR, total and phosphorylated forms were assessed, respectively, by: motor behavior testing, histological reactions, Real-time PCR and Western Blotting analysis. Results: Dexamethasone administration induced significant decrease of small motor movements, atrophy in type IIB muscle fibers and decrease of P-Akt, P-GSK3omega and P-FOXO3a/total FOXO3a expression. Omega-3 supplementation was not able to attenuate these changes. Instead, omega-3 associated to dexamethasone (DX+ omega-3 group) additionally induced higher muscle atrophy in type I, IIA muscle fibers, and reduced expression of Myogenin. The isolated use of Omega-3 led to a significant higher expression of Myostatin and MyoD, and a non-significant increase of total mTOR protein expression and less body weight gain at end of study. Conclusion: Supplementation of omega-3 was not able to attenuate motor behavioral changes, muscle atrophy and loss of body weight caused by dexamethasone administration, leading on the other hand to higher muscle fibers atrophy and increase in atrogenes expression. Therefore, this study suggests that food supplements, usually considered benefic to the health, such as Omega-3 fatty acid, may interact with some medications, such as glucocorticoids, potentiating its side effects Ácidos graxos ômega-3/efeitos adversos Atrofia muscular/genética Atrofia muscular/induzido quimicamente Atrofia muscular/patologia Blotting western Dexametasona/efeitos adversos Dexamethasone/adverse effects Fatores de transcrição Forkhead Fatty acids omega-3/adverse effects Forkhead transcription factors Glucocorticoides Glucocorticoids Muscle skeletal/drugs effects Muscular atrophy/chemically induced Muscular atrophy/genetics Muscular atrophy/pathology Músculo esquelético/efeitos de drogas Ratos Wistar Rats Wistar Real-time polymerase chain reaction Ubiquitin-protein ligases Ubiquitina-proteína ligases/genética Western Blotting
462	Efeitos do ácido graxo ômega-3 na prevenção da atrofia muscular induzida pela dexametasona / Effects of omega-3 fatty acid in preventing dexamethasone-induced muscle atrophy Alan Fappi 03 December 2013 (has links) Várias condições podem estar associadas com a atrofia muscular, tais como inatividade, envelhecimento, septicemia, diabetes, câncer e uso de glicocorticoides. Todas estas condições levam a atrofia muscular através de mecanismos que incluem aumento da degradação proteica e/ou redução na síntese proteica, envolvendo pelo menos cinco sistemas: lisossomal, da calpaína, das caspases, metaloproteinases e o sistema ubiquitina-proteasoma (SUP). Glicocorticoides, tais como a dexametasona, acarretam atrofia muscular atuando em quase todos esses sistemas, com significante ativação do SUP e lisossomal, afetando uma importante via de trofismo muscular, a via do IGF-1/PI-3K/Akt/mTOR. Ácidos graxos poli-insaturados, como o Ômega-3 (ômega-3), têm sido utilizados de forma benéfica na atenuação da atrofia muscular que ocorre na septicemia e na caquexia associada ao câncer, no entanto, sua atuação sobre a atrofia muscular induzida por glicocorticoides ainda não foi avaliada. Objetivo: Avaliar se a suplementação do ácido graxo ômega-3 influenciaria o desenvolvimento da atrofia muscular induzida pela dexametasona em ratos. Metodologia: Vinte e quatro ratos Wistar suplementados e não suplementados com ômega-3 (40 dias) foram submetidos à administração de dexametasona subcutânea (5mg/Kg/dia) nos últimos 10 dias, formando assim quatro grupos: Controle (CT), dexametasona (DX), ômega3 e dexametasona+ômega3 (DX+ômega3). Através de estudo de comportamento motor, histológico, PCR em tempo real e Western Blotting foram avaliados respectivamente, o número de grandes e pequenos movimentos em campo aberto; a área de secção transversa das fibras musculares (fibras I, IIA e IIB); a expressão dos genes MyoD, Miogenina, MuRF-1, Atrogina-1 e Miostatina; e a expressão de proteínas relacionadas com a via do IGF-1/PI-3K/Akt/mTOR: Akt, GSK3beta, FOXO3a e mTOR, totais e fosforiladas. Resultados: A dexametasona produziu diminuição na quantidade de pequenos movimentos, atrofia muscular em fibras do tipo IIB e diminuição na expressão de P-Akt, P-GSK3ômega e P-FOXO3a/FOXO3a total. A suplementação com Ômega-3 não se mostrou eficaz na atenuação de tais alterações. Por outro lado, o Ômega-3 associado à dexametasona (grupo DX+3) induziu a maior expressão de atrogenes (MuRF-1 e atrogina-1) causando, adicionalmente, maior atrofia muscular em fibras do tipo I e IIA, além de menor expressão gênica de Miogenina. O Ômega-3 de forma isolada conduziu de forma significativa a maior expressão de Miostatina e MyoD, e de forma não significante elevou a expressão proteica de mTOR total e induziu menor ganho de peso corporal dos animais ao fim do estudo. Conclusão: A suplementação de Ômega-3 não foi capaz de atenuar as alterações comportamentais, atrofia muscular e perda de peso corporal causadas pela administração de dexametasona, levando por outro lado a maior atrofia das fibras musculares e aumento na expressão de atrogenes. Desta forma, este estudo sugere que suplementos alimentares usualmente considerados benéficos para saúde, tal como o ácido graxo Ômega-3, podem agir em interação com alguns medicamentos, como os glicocorticoides, potencializando seus efeitos colaterais / Many conditions can be related to muscle atrophy, such as inactivity, aging, sepsis, diabetes, cancer, as well as, glucocorticoid treatment. All these conditions lead to muscle atrophy through mechanisms that include increase of protein degradation and/or decrease of protein synthesis involving at least five systems: lysossomal, calpain, caspases, metaloproteinases and ubiquitin proteasome system (UPS). Glucocorticoids, such as dexamethasone cause muscle atrophy acting in almost all of these systems, with a significant UPS activation and affecting an important pathway related to muscular trophism, IGF-1/PI-3k/Akt/mTOR pathway. Poly-unsaturated fatty acids, such as Omega-3 (omega-3), have been used beneficially to attenuation of muscle atrophy that occur in sepsis and cachexia related to cancer, however, its action in the glucocorticoid-induced muscle atrophy, has never been evaluated. Objective: Assess whether the omega-3 supplementation would influence the development of dexamethasone-induced muscle atrophy in rats. Methods: Twenty four Wistar rats supplemented and non-supplemented with omega-3 (40 days) were submitted to dexamethasone administration (5mg/kg/day) during the last 10 days, thus establishing 4 groups: control (CT), dexamethasone (DX), omega-3 and dexamethasone+omega-3 (DX+ omega-3). The amount of large and small movements in open field; muscle fiber cross sectional areas (I, IIA and IIB); MyoD, Myogenin, MuRF-1, Atrogin-1 and Myostatin gene expression; and protein expression of Akt, GSK3omega, FOXO3a and mTOR, total and phosphorylated forms were assessed, respectively, by: motor behavior testing, histological reactions, Real-time PCR and Western Blotting analysis. Results: Dexamethasone administration induced significant decrease of small motor movements, atrophy in type IIB muscle fibers and decrease of P-Akt, P-GSK3omega and P-FOXO3a/total FOXO3a expression. Omega-3 supplementation was not able to attenuate these changes. Instead, omega-3 associated to dexamethasone (DX+ omega-3 group) additionally induced higher muscle atrophy in type I, IIA muscle fibers, and reduced expression of Myogenin. The isolated use of Omega-3 led to a significant higher expression of Myostatin and MyoD, and a non-significant increase of total mTOR protein expression and less body weight gain at end of study. Conclusion: Supplementation of omega-3 was not able to attenuate motor behavioral changes, muscle atrophy and loss of body weight caused by dexamethasone administration, leading on the other hand to higher muscle fibers atrophy and increase in atrogenes expression. Therefore, this study suggests that food supplements, usually considered benefic to the health, such as Omega-3 fatty acid, may interact with some medications, such as glucocorticoids, potentiating its side effects Ácidos graxos ômega-3/efeitos adversos Atrofia muscular/genética Atrofia muscular/induzido quimicamente Atrofia muscular/patologia Dexametasona/efeitos adversos Fatores de transcrição Forkhead Glucocorticoides Músculo esquelético/efeitos de drogas Ratos Wistar Ubiquitina-proteína ligases/genética Western Blotting Blotting western Dexamethasone/adverse effects Fatty acids omega-3/adverse effects Forkhead transcription factors Glucocorticoids Muscle skeletal/drugs effects Muscular atrophy/chemically induced Muscular atrophy/genetics Muscular atrophy/pathology Rats Wistar Real-time polymerase chain reaction Ubiquitin-protein ligases
463	Effet des acides gras oméga-3 sur l’inflammasome NLRP3 et les facteurs de risque de diabète de type 2 chez l’humain : modèles in vivo et ex vivo Lamantia, Valérie 12 1900 (has links) Contexte : La dysfonction du tissu adipeux blanc (TAB) favorise les facteurs de risque de diabète de type 2 (DbT2), c’est-à-dire la résistance à l’insuline (RI), l’hyper sécrétion d’insuline glucostimulée (SIGS), le délai de clairance des gras et les concentrations élevées d’apoBlipoprotéines (apoB plasmatique) incluant les lipoprotéines de faible densité (LDL). De récentes études de notre laboratoire et d’autres suggèrent que le niveau élevé d’apoB plasmatique (hyperapoB) est une cause et non seulement une conséquence de la dysfonction du TAB. De plus, une internalisation augmentée d’apoB-lipoprotéines via les récepteurs tels que le récepteur aux LDLs (LDLR) et le cluster de différenciation 36 (CD36), favorise le risque de DbT2. Cependant, les mécanismes sous-jacents de même que les interventions nutritionnelles pour les cibler demeurent incertains. L'activation de la voie de l’inflammasome NLRP3/ interleukine (IL) -1β favorise la dysfonction du TAB et les facteurs de risque de DbT2 et est activée par les LDLs oxydées dans les cellules immunitaires. L'acide eicosapentaénoïque (AEP) et l'acide docosahexaénoïque (ADH) réduisent l'hyperapoB, l'activité de l’inflammasome NLRP3 dans les cellules immunitaires et les facteurs de risque de DbT2 chez l’humain. Ils sont synthétisés de façon endogène par l’entremise des désaturases d’acides gras δ-5 (D5D) et δ-6 (D6D). Chez l’humain, de faibles niveaux d’AEP et d’ADH circulants et d’activité de la D5D et une activité élevée de la D6D prédisent l'incidence de DbT2 et la RI par des mécanismes inconnus. Objectifs : L'hypothèse de ma thèse est que l'AEP et l’ADH améliorent les facteurs de risque de DbT2, soit la dysfonction du TAB, le délai de clairance des gras, la RI et l’hyper SIGS, ceci via une baisse de l'apoB plasmatique et de l’activité de l’inflammasome NLRP3 dans le TAB. Les objectifs sont d'examiner si: 1) les associations entre les activités de la D5D et de la D6D et les facteurs de risque de DbT2 dépendent de l'apoB plasmatique; 2) la supplémentation en AEP+ADH réduit l'apoB plasmatique, l'expression du LDLR et du CD36 dans le TAB, l'activité de l’inflammasome NLRP3 dans le TAB et les facteurs de risque de DbT2; 3) l’AEP+ADH inhibe la sécrétion d'IL-1β par le TAB humain stimulée par des signaux canoniques ou les LDLs natives. Méthodes: Des hommes et des femmes postménopausées normoglycémiques ont été testés à l’état basal et après une supplémentation en AEP (1,8 g/jour) et ADH (0,9 g/jour) de 12 semaines. Les activités de la D5D et de la D6D ont été estimées à partir des acides gras produits/précurseurs dans les phospholipides plasmatiques. Nous avons mesuré la SIGS, la RI et le disposition index lors d’un clamp Botnia. Après un repas à 66% de gras, le délai de clairance des gras a été mesuré par l’aire sous la courbe (sur 6 h) des triglycérides (TG) ou de l’apoB48 (chylomicrons) plasmatiques. Ex vivo dans une biopsie de TAB, nous avons mesuré l'expression de surface du LDLR et du CD36 par immunohistochimie, l'ARNm de NLRP3 et IL1B par RT-qPCR et la sécrétion d'IL-1β par alpha-LISA en l’absence ou en présence d’une stimulation par le lipopolysaccharide (LPS), l'adénosine triphosphate (ATP) et/ou les LDLs humaines natives et lors d’une co-incubation avec l’AEP+ADH. Résultats: À l’état basal (N=98), l'activité de la D5D corrélait négativement avec l'apoB plasmatique, la 2e phase de SIGS, la RI et le délai de clairance des chylomicrons et ces associations étaient dépendantes de l'apoB plasmatique. Inversement, l'activité de la D6D corrélait positivement avec la SIGS, la RI et le délai de clairance des chylomicrons indépendamment de l'apoB plasmatique. Chez les sujets ayant complété la supplémentation en AEP+ADH (N=30), on notait une amélioration de la 1e phase de SIGS, du disposition index et de la clairance des TGs. Des niveaux initiaux plus élevés d'apoB plasmatique, de TGs postprandiaux plasmatiques et de RI, et dans le TAB d'expression du LDLR et du CD36, de sécrétion d’IL-1β et d'ARNm de NLRP3 prédisaient une plus grande réduction de ces paramètres. En comparaison à l'acide palmitique, l’AEP+ADH inhibait la sécrétion d'IL-1β par le TAB, en l’abscence ou en présence d’une stimulation par le LPS, l'ATP et/ou les LDLs natives de ces sujets. Conclusion: Les associations inverses entre l'activité de la D5D avec les facteurs de risque de DbT2 sont dépendantes de l'apoB plasmatique. Les meilleurs répondants à la supplémentation en AEP et ADH, en termes de réduction d'apoB plasmatique, d’expression du LDLR et du CD36 dans le TAB, d'activité de l’inflammasome NLRP3 dans le TAB, de TGs postprandiaux et de RI, sont les sujets avec des niveaux initiaux élevés de ces paramètres. L’AEP et l’ADH inhibent directement la sécrétion d'IL-1β par le TAB humain induite par les LDLs natives ou d'autres signaux. Nous proposons que la supplémentation en AEP et ADH puisse cibler l'activité de l’inflammasome NLRP3 dans le TAB, induite par un niveau élevé d’apoB-lipoprotéines plasmatiques ou internalisées par les récepteurs, et ainsi aider à prévenir le DbT2. / Background: White adipose tissue (WAT) dysfunction promotes risk factors for type 2 diabetes (T2D), namely insulin resistance (IR), high glucose-stimulated insulin secretion (GIIS), delayed fat clearance and high concentrations of apoB-lipoproteins (measured as plasma apoB) including low density lipoproteins (LDL). Recent studies from our lab and others suggest that high plasma apoB (hyperapoB) is a cause and not only a consequence of WAT dysfunction. Moreover, upregulated receptor-mediated uptake of apoB-lipoproteins via LDL receptor (LDLR) and cluster of differentiation 36 (CD36), promotes the risk for T2D. However, underlying mechanisms as well as nutritional interventions to target them remain unclear. Activation of the NLRP3 inflammasome/interleukin (IL)-1β pathway promotes WAT dysfunction and risk factors for T2D and is activated by oxidized LDLs in immune cells. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduce hyperapoB, NLRP3 inflammasome activity in immune cells and risk factors for T2D in humans. They are synthesized endogenously through δ-5 (D5D) and δ-6 (D6D) fatty desaturases. In humans, low levels of circulating EPA and DHA and D5D activity and high D6D activity predict the incidence of T2D and IR by unknown mechanisms. Objectives: The hypothesis of my thesis is that EPA and DHA improve T2D risk factors, namely WAT dysfunction, delayed fat clearance, IR and high GIIS, this via a reduction of plasma apoB and WAT NLRP3 inflammasome activity. The objectives are to examine whether: 1) the associations between the levels of D5D and D6D activities and the risk factors for T2D are dependent on plasma apoB; 2) supplementation with EPA+DHA reduces plasma apoB, WAT LDLR and CD36 expression, WAT NLRP3 inflammasome activity and T2D risk factors; 3) EPA+DHA directly inhibits IL-1β secretion from human WAT stimulated by canonical signals or native LDLs. Methods: Normoglycemic men and postmenopausal women were tested at baseline and after supplementation with EPA (1.8 g/day) and DHA (0.9 g/day) for 12 weeks. The activities of D5D and D6D were estimated from the product/precursor fatty acids in plasma phospholipids. We measured GIIS, IR and disposition index by a Botnia clamp. Following a 66% fat meal, delayed fat clearance was measured as the area under the curve (over 6 h) of plasma triglycerides (TG) or apoB48 (chylomicrons). Ex vivo in a WAT biopsy, we measured LDLR and CD36 surface expression by immunohistochemistry, NLRP3 and IL1B mRNA by RT-qPCR, and IL-1β secretion by alpha-LISA either unstimulated or stimulated by lipopolysaccharide (LPS), adenosine triphosphate (ATP), and/or native human LDLs, and during co-incubation with EPA+DHA. Results: At baseline (N=98), D5D activity correlated negatively with plasma apoB, 2nd phase GIIS, IR and delayed chylomicron clearance and these associations were dependent on plasma apoB. Conversely, D6D activity correlated positively with GIIS, IR, and delayed chylomicron clearance independently of plasma apoB. In subjects who completed the EPA+DHA supplementation (N=30), there was an amelioration in 1st phase GIIS, disposition index and TG clearance. Higher baseline levels of plasma apoB, plasma postprandial TGs, IR, WAT LDLR and CD36 surface expression, WAT IL-1β secretion and WAT NLRP3 mRNA predicted a greater reduction of these parameters. In comparison with palmitic acid, EPA+DHA inhibited IL-1β secretion from WAT, either unstimulated or stimulated by LPS, ATP and/or subjects’ native LDLs. Conclusion: The negative associations of D5D activity with risk factors for T2D are dependent on plasma apoB. Best responders to EPA and DHA supplementation to reduce plasma apoB, WAT LDLR and CD36 expression, WAT NLRP3 inflammasome activity, delayed TG clearance, and IR are subjects with elevated baseline levels of these parameters. EPA and DHA directly inhibit IL-1β secretion from human WAT induced by native LDLs or other signals. We propose that EPA and DHA supplementation may target upregulated WAT NLRP3 inflammasome activity induced by high plasma concentrations, or receptor-mediated uptake, of apoB-lipoproteins, and thus help prevent T2D. acide eicosapentaénoïque acide docosahexaénoïque désaturase d’acides gras δ-5 désaturase d’acides gras δ-6 apolipoprotéine B (apoB) lipoprotéines de faible densité (LDL) inflammasome NLRP3 interleukine-1β acides gras polyinsaturés oméga-3 diabète de type 2 tissu adipeux blanc inflammation résistance à l'insuline sécrétion d'insuline métabolisme postprandial des gras omega-3 polyunsaturated fatty acids eicosapentaenoic acid docosahexaenoic acid δ-5 fatty acid desaturase δ-6 fatty acid desaturase apolipoprotein B (apoB) low density lipoprotein (LDL) NLRP3 inflammasome interleukin-1β type 2 diabetes white adipose tissue insulin resistance insulin secretion postprandial fat metabolism
464	GRAVIDA KVINNORS INTAG AV KOSTTILLSKOTT : En kvantitativ studie med fokus på järn och probiotika / PREGNANT WOMEN´S INTAKE OF DIETARY SUPPLEMENT : A quantitative study focusing on iron and probiotics Lange Bålman, Miriam January 2019 (has links) Sammanfattning Bakgrund Vitamin- och mineralbrister hos gravida kvinnor kan leda till missfall och allvarliga störningar i barnets utveckling. Moderns tarmflora överförs med stor sannolikhet till barnet under förlossningen och kan därför innebära ett viktigt steg i utvecklingen av barnets tarmflora. En tänkbar lösning för att säkra ett adekvat intag kan vara konsumtion av kosttillskott och probiotika. I dagsläget finns osäkra uppgifter om hur många gravida kvinnor som intar tillskott. Syfte Att undersöka hur många gravida kvinnor i Västerbottens län som valde att inta kosttillskott, främst järn och probiotika, samt om det fanns en skillnad mellan olika faktorer och intag. Metod En kvantitativ tvärsnittsstudie där gravida kvinnor (n=1473) från Northpop-studien i Västerbottens län svarade på ett frågeformulär gällande intag av kosttillskott och faktorer som ålder, utbildning, kostregim etc. De statistiska tester som användes var Chi-2-test, oberoende t-test och Mann Whitney U-test. Materialet analyserades i SPSS. Signifikansnivån sattes till p<0,05. Resultat Majoriteten av deltagarna svarade att de intog kosttillskott. Faktorer som ökade intaget av kosttillskott hos gravida kvinnor var högre ålder (p=0,030) jämfört med lägre ålder, högre utbildningsnivå (p=0,006) jämfört med lägre utbildningsnivå och vegetarisk/vegansk kost (p=0,021) jämfört med blandkost. Femtiofem procent uppgav att de intog järntillskott. De faktorer som ökade intaget av järntillskott hos gravida kvinnor var vegetarisk/vegansk kost (p=0,001) jämfört med blandkost. Probiotika intogs av 2 procent. Ett högre intag av probiotika sågs hos personer boende i stadsområde (p=0,024) jämfört med övriga boenderegioner samt de som åt vegetarisk/vegansk kost (p=0,001) jämfört med blandkost. Slutsats Majoriteten av deltagarna intog någon typ av kosttillskott, hälften intog järntillskott och en liten andel intog probiotika. Lågutbildade, yngre, de som äter blandkost och bor utanför stadsområde verkar vara i riskgruppen för att inte inta kosttillskott. / Abstract Background Vitamin and mineral deficiencies in pregnant women can lead to miscarriage and serious disturbances in children’s development. The intestinal flora of the mother is most likely transmitted to the child during childbirth and may lay the foundation for the child's health. One possible solution to ensure an adequate intake may be the consumption of dietary supplements and probiotics. At present, there is insufficient data on supplement consumption among pregnant women. Objective The purpose of the study was to examine how many pregnant women in Västerbotten County chose to consume dietary supplements, mainly iron and probiotics, and whether there was a difference between different factors and intake. Method A quantitative cross-sectional study where pregnant women (n=1473) from the Northpop-study in Västerbotten County responded to a questionnaire regarding consumption of dietary supplements and factors such as age, education, diet etc. The material was analyzed in SPSS with Chi-2-test, independent T-Test and Mann-Whitney U-Test. Using significance level <0.05. Results The majority of participants, 90 percent, responded that they consumed dietary supplements. The factors that increased the intake of dietary supplements in pregnant women were higher age (p=0.030), higher education (p=0.006) and vegetarian/vegan diet (p=0.021). Iron was reported to be consumed by 804 people, 55 percent. The factors that increased the intake of iron supplement in pregnant women were vegetarian/vegan diet (p=0.001). Probiotics were consumed by 25 people, 2 percent. Living in urban areas (p=0.024) and eating vegetarian/vegan diet (p=0.002) increased consumption of probiotics. Conclusion The majority of participants chose to consume some type of dietary supplement, half of the participants consumed iron supplements and a small part consumed probiotics. It appears that pregnant women who are low educated, younger, eating an omnivorous diet and living outside urban areas are in the risk zone for not consuming dietary supplements. / Northpop Pregnant pregnant women woman pregnancy children fetus dietary supplements supplements iron iron supplements probiotics probiotic supplements intestinal flora bacteria gut vitamin vitamins minerals minerals B12 folate diet education low educated highly educated region age intake diet regime northpop Västerbotten Västerbotten County Council Umeå University Umeå Sweden Miriam Lange Bålman Miriam Lange Balman science economist vegetarian vegan mixed diet omnivore urban area country side quantitative nutrition diet dietician dietetics quantitative nutrition diet Chi-2 test independent t-test Mann Whitney U-test Multivitamins (mixture of vitamins) Multi-minerals (blend of minerals) Probiotics Omega-3 fish oil Blutsaft A- vitamin B vitamin vitamin C vitamin D vitamin E folic acid iron calcium beta-carotene vitamin B complex selenium antioxidants zinc magnesium q10 exercise physical activity lifestyle bachelor essay Gravid gravida kvinnor kvinna graviditet foster barn kosttillskott tillskott järn järntillskott probiotika probiotikatillskott tarmflora bakterier tarm vitamin vitaminer mineral mineraler B12 folat kost utbildning lågutbildad högutbildad boenderegion stad landsbygd ålder intag kostregim northpop Västerbotten Västerbottens läns landsting Umeå universitet Umeå Sverige Miriam Lange Bålman Miriam Lange Bålman kostvetenskap kostekonom vegetarisk vegetariskt vegan veganskt blandkost stadsområde kvantitativ näring samhällsrelevans dietist dietetik Chi-2-test oberoende t-test Mann Whitney U-test Multivitaminer (blandning av vitaminer) Multimineraler (blandning av mineraler) Probiotika Omega-3 fiskolja Blutsaft A-vitamin B-vitamin C-vitamin D-vitamin E-vitamin Folsyra Järn Kalcium Betakaroten Vitamin B-komplex Selen Antioxidanter Zink Magnesium Q10 träning fysisk aktivitet livsstil uppsats kandidatexamen Nutrition and Dietetics Näringslära
465	A case for memory enhancement : ethical, social, legal, and policy implications for enhancing the memory Muriithi, Paul Mutuanyingi January 2014 (has links) The desire to enhance and make ourselves better is not a new one and it has continued to intrigue throughout the ages. Individuals have continued to seek ways to improve and enhance their well-being for example through nutrition, physical exercise, education and so on. Crucial to this improvement of their well-being is improving their ability to remember. Hence, people interested in improving their well-being, are often interested in memory as well. The rationale being that memory is crucial to our well-being. The desire to improve one’s memory then is almost certainly as old as the desire to improve one’s well-being. Traditionally, people have used different means in an attempt to enhance their memories: for example in learning through storytelling, studying, and apprenticeship. In remembering through practices like mnemonics, repetition, singing, and drumming. In retaining, storing and consolidating memories through nutrition and stimulants like coffee to help keep awake; and by external aids like notepads and computers. In forgetting through rituals and rites. Recent scientific advances in biotechnology, nanotechnology, molecular biology, neuroscience, and information technologies, present a wide variety of technologies to enhance many different aspects of human functioning. Thus, some commentators have identified human enhancement as central and one of the most fascinating subject in bioethics in the last two decades. Within, this period, most of the commentators have addressed the Ethical, Social, Legal and Policy (ESLP) issues in human enhancements as a whole as opposed to specific enhancements. However, this is problematic and recently various commentators have found this to be deficient and called for a contextualized case-by-case analysis to human enhancements for example genetic enhancement, moral enhancement, and in my case memory enhancement (ME). The rationale being that the reasons for accepting/rejecting a particular enhancement vary depending on the enhancement itself. Given this enormous variation, moral and legal generalizations about all enhancement processes and technologies are unwise and they should instead be evaluated individually. Taking this as a point of departure, this research will focus specifically on making a case for ME and in doing so assessing the ESLP implications arising from ME. My analysis will draw on the already existing literature for and against enhancement, especially in part two of this thesis; but it will be novel in providing a much more in-depth analysis of ME. From this perspective, I will contribute to the ME debate through two reviews that address the question how we enhance the memory, and through four original papers discussed in part three of this thesis, where I examine and evaluate critically specific ESLP issues that arise with the use of ME. In the conclusion, I will amalgamate all my contribution to the ME debate and suggest the future direction for the ME debate. 174

Page generated in 0.0396 seconds